Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 16/20 | 0.42 |
| ▸ | RXRG | P48443 | 9/20 | 0.42 |
| ▸ | RXRB | P28702 | 8/20 | 0.42 |
| ▸ | RARA | P10276 | 4/20 | 0.42 |
| ▸ | RARB | P10826 | 3/20 | 0.42 |
| ▸ | RARG | P13631 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29539383 | 1.00 | CYP3A4 (0.44) | CYP3A4TSHRMAPK1RXRARXRG | |
| SCHEMBL9867812 | 0.85 | PTK2 (0.44) | CYP3A4RXRARXRGRXRBRARA | |
| SCHEMBL7622765 | 0.83 | RXRA (0.48) | RXRARXRGRXRBRARARARB | |
| SCHEMBL31675854 | 0.80 | RXRA (0.42) | CYP3A4RXRARXRGRXRBRARA | |
| SCHEMBL9054373 | 0.80 | RXRA (0.42) | CYP3A4RXRARXRGRXRBRARA | |
| SCHEMBL3170254 | 0.77 | RXRA (0.44) | RXRARXRGRXRBRARARARB | |
| SCHEMBL21440625 | 0.77 | RXRA (0.38) | CYP3A4RXRARXRGRXRBRARA | |
| SCHEMBL6330023 | 0.77 | RXRA (0.48) | CYP3A4TSHRMAPK1RXRARXRG | |
| SCHEMBL9867919 | 0.76 | RXRA (0.44) | CYP3A4RXRARXRGRXRBRARA | |
| SCHEMBL9053254 | 0.76 | GAA (0.46) | CYP3A4TSHRMAPK1RXRARXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637482-B2 | Compound and organic light emitting device comprising same | LG CHEM, LTD. (KR) | 2026-05-26 | — | — | US | disclosed |
| US-12559467-B2 | Organic light emitting device | LG CHEM, LTD. (KR) | 2026-02-24 | — | — | US | disclosed |
| US-12563964-B2 | Organic light-emitting device | LG CHEM, LTD. (KR) | 2026-02-24 | — | — | US | disclosed |
| US-12522764-B2 | Compound and organic light emitting device comprising same | LG CHEM, LTD. (KR) | 2026-01-13 | — | — | US | disclosed |
| US-12497415-B2 | Polycyclic compound and organic light-emitting element comprising same | LG CHEM, LTD. (KR) | 2025-12-16 | — | — | US | disclosed |
| EP-3919500-B1 | COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEMICAL LTD (KR) | 2024-08-28 | — | — | EP | disclosed |
| EP-3909958-B1 | COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEMICAL LTD (KR) | 2023-12-27 | — | — | EP | disclosed |
| EP-4265624-A1 | COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | Lg Chem, Ltd. (KR) | 2023-10-25 | — | — | EP | disclosed |
| US-11780856-B2 | Compound and organic light-emitting device comprising same | LG CHEM, LTD. (KR) | 2023-10-10 | — | — | US | disclosed |
| US-11780856-B2 | Compound and organic light-emitting device comprising same | LG CHEM, LTD. (KR) | 2023-10-10 | — | — | US | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
| EP-1180520-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES | Institute of Medicinal Molecular Design, Inc. (JP) | 2002-02-20 | — | — | EP | disclosed |
| US-5498755-A | IMINE COMPOUNDS FOR SKIN DISORDERS AND ANTIINFLAMMATORY AGENTS | ALLERGAN, INC. | 1996-03-12 | — | — | US | disclosed |
| WO-1996006070-A1 | DISUBSTITUTED ARYL AND HETEROARYL IMINES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1996-02-29 | — | — | WO | disclosed |
| US-RE33533-E | Skin disorders | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (CIRD) (FR) | 1991-02-05 | — | — | US | disclosed |
| EP-0292348-B1 | POLYCYCLIC HETEROCYCLIC DERIVATIVES, PROCES FOR THEIR PREPARATION AND THEIR USE IN HUMAN AND VETERINARY MEDICINES | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA Groupement d'Intérêt Economique dit: (FR) | 1990-09-19 | — | — | EP | disclosed |
| US-4874747-A | DERMATOLOGY | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (CIRD) (FR) | 1989-10-17 | — | — | US | disclosed |
| EP-0292348-A1 | Polycyclic heterocyclic derivatives, proces for their preparation and their use in human and veterinary medicines | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA Groupement d'Intérêt Economique dit: (FR) | 1988-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637482-B2 | Compound and organic light emitting device comprising same | NR1H2, NR1H3, NR2E3 | CYP3A4 638/4885TSHR 175/4885MAPK1 4353/4885 |
| US-12497415-B2 | Polycyclic compound and organic light-emitting element comprising same | CYBA, CRY2, CRY1 | CYP3A4 7/4885TSHR 4014/4885MAPK1 2779/4885 |
| US-12563964-B2 | Organic light-emitting device | CRY1, CYP1A1, CTNNA1 | CYP3A4 126/4885TSHR 2629/4885MAPK1 874/4885 |
| US-11780856-B2 | Compound and organic light-emitting device comprising same | CRY1, CRY2, LEF1 | CYP3A4 27/4885TSHR 4847/4885MAPK1 277/4885 |
| US-12559467-B2 | Organic light emitting device | CRY1, RPS24, ARL1 | CYP3A4 678/4885TSHR 1707/4885MAPK1 2213/4885 |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | CYP3A4 1988/4885TSHR 4035/4885MAPK1 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.